The Ketamine Cousin: DEA Triggers Emergency Schedule I Control Over 2-FDCK

International treaty obligations forced the agency's hand just as heavily as domestic health data. The Secretariat of the United Nations formally notified the U.S. State Department that the Commission on Narcotic Drugs voted to place the substance in Schedule II of the 1971 Convention on Psychotropic Substances. As a signatory to the treaty, the United States is legally bound to align its domestic framework with international controls. To meet these minimum treaty requirements and avoid an imminent hazard to public safety, the DEA opted for the temporary, emergency scheduling route rather than the protracted notice-and-comment rulemaking process. Temporary scheduling orders of this nature carry a unique administrative shield, as they are not subject to judicial review. The regulatory blueprint for this ban rests on the pharmacological reality that 2-FDCK mirrors the dissociative and hallucinogenic properties of phencyclidine and ketamine. The Department of Health and Human Services and the Food and Drug Administration conducted updated reviews confirming the chemical lacks any accepted medical use, investigational new drug applications, or approved new drug applications in the United States. Stripped of any recognized medical utility, the substance’s profile is defined entirely by its illicit market presence. Forensic laboratories have documented sixty-one seizures across twelve states since 2018, and toxicological data explicitly links the chemical to three polysubstance overdose cases, two of which were fatal. Law enforcement tracking also indicates the substance is frequently utilized as a clandestine adulterant, a ketamine substitute, and has been identified in international cases of drug-facilitated sexual assault. The operational reality for domestic laboratories, chemical importers, and research institutions shifts completely as of today. Any person or entity interacting with the substance must be explicitly registered with the DEA. The agency has carved out a narrow, ninety-day administrative safe harbor strictly for researchers who already possess a Schedule I registration for other substances. Provided they submit an application to modify their existing registration to include 2-FDCK within that window, these specific researchers may continue their work until the Administrator formally rules on their application. For all other entities, the regulatory hammer drops immediately, requiring the total surrender of all currently held stocks if a registration cannot be obtained. Stringent compliance mechanisms are now in active enforcement. The DEA has mandated that all physical security requirements for Schedule I substances apply to 2-FDCK immediately. The agency has provided a brief thirty-day grace period for current registrants to bring their commercial packaging, labeling, and inventory auditing into full compliance with federal standards. From a supply chain perspective, only manufacturers operating under a specifically assigned DEA quota are permitted to synthesize the chemical moving forward. Any unauthorized activity involving the substance as of this morning exposes the handler to the full spectrum of federal administrative, civil, and criminal liability.